Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00285
|
|||||
| Drug Name |
Silodosin
|
|||||
| Synonyms |
(R)-1-(3-hydroxypropyl)-5-(2-((2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethyl)amino)propyl)indoline-7-carboxamide; 1-(3-hydroxypropyl)-5-[(2R)-2-[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethylamino]propyl]-2,3-dihydroindole-7-carboxamide; 160970-64-9; CHEMBL24778; CUZ39LUY82; KAD 3213; KAD-3213; KMD 3213; KMD-3213; Q-102517; Rapaflo; Rapflo; Silodosin-d6; Silodyx; UNII-CUZ39LUY82; Urief; Urorec
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | Benign prostatic hyperplasia [ICD11:GA90] | Approved | [1] | |||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C25H32F3N3O4
|
|||||
| Canonical SMILES |
CC(CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F
|
|||||
| InChI |
InChI=1S/C25H32F3N3O4/c1-17(30-8-12-34-21-5-2-3-6-22(21)35-16-25(26,27)28)13-18-14-19-7-10-31(9-4-11-32)23(19)20(15-18)24(29)33/h2-3,5-6,14-15,17,30,32H,4,7-13,16H2,1H3,(H2,29,33)/t17-/m1/s1
|
|||||
| InChIKey |
PNCPYILNMDWPEY-QGZVFWFLSA-N
|
|||||
| CAS Number |
CAS 160970-54-7
|
|||||
| Pharmaceutical Properties | Molecular Weight | 495.5 | Topological Polar Surface Area | 97 | ||
| Heavy Atom Count | 35 | Rotatable Bond Count | 13 | |||
| Hydrogen Bond Donor Count | 3 | Hydrogen Bond Acceptor Count | 9 | |||
| XLogP |
3.6
|
|||||
| PubChem CID | ||||||
| PubChem SID |
103194366
,104046714
,109693099
,11056891
,114157936
,12014894
,126623000
,126665711
,128939931
,131300819
,134339064
,134340151
,134342132
,135252710
,135368407
,135650458
,135916576
,137248544
,142093997
,14810706
,14835413
,152258092
,152344280
,160646931
,162011672
,162172235
,162223757
,163884568
,164765008
,164777753
,172085148
,174527805
,175266679
,175427058
,175612190
,179150028
,184816547
,187071911
,198991703
,202821102
,211536181
,223392962
,223484371
,39341745
,57359519
,7849027
,7979683
,80176928
,92098546
,99299508
|
|||||
| ChEBI ID |
CHEBI:135929
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | MDR3 | Transporter Info | Multidrug resistance protein 3 | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Silodosin was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | Pharmacokinetics and disposition of silodosin (KMD-3213)]. Yakugaku Zasshi. 2006 Mar;126 Spec no.:237-45. | |||||
| 3 | The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. Drug Metab Pharmacokinet. 2013;28(3):239-43. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.